Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Treace Medical Concepts (TMCI) EPS (Weighted Average and Diluted) (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.14 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 1300.0% year-over-year to -$0.14, compared with a TTM value of -$0.93 through Dec 2025, down 3.33%, and an annual FY2025 reading of -$0.93, down 3.33% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.14 for Q4 2025 at Treace Medical Concepts, up from -$0.26 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.01 in Q4 2024 and bottomed at -$0.34 in Q2 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.2, with a median of -$0.22 recorded in 2022.
  • The sharpest move saw EPS (Weighted Average and Diluted) surged 90.0% in 2024, then plummeted 1300.0% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.13 in 2021, then skyrocketed by 46.15% to -$0.07 in 2022, then crashed by 42.86% to -$0.1 in 2023, then soared by 90.0% to -$0.01 in 2024, then tumbled by 1300.0% to -$0.14 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for TMCI at -$0.14 in Q4 2025, -$0.26 in Q3 2025, and -$0.28 in Q2 2025.